MAPK Inhibitors Restore CAR T-Cell Target in Thyroid Cancer Models
Trametinib and dabrafenib increased TSHR expression and improved the activity of CAR T cells in a patient-derived model of anaplastic thyroid cancer
Clinical Scorecard: MAPK Inhibitors Restore CAR T-Cell Target in Thyroid Cancer Models
At a Glance
| Category | Detail |
|---|
| Condition | Thyroid Cancer |
| Key Mechanisms | Restoration of TSHR expression using MAPK inhibitors to enhance CAR T-cell therapy efficacy. |
| Target Population | Patients with aggressive thyroid cancer, particularly anaplastic thyroid cancer. |
| Care Setting | Preclinical study evaluating treatment strategies. |
Key Highlights
- MAPK inhibitors can restore TSHR expression in aggressive thyroid cancer cells.
- Combining MAPK inhibitors with TSHR-directed CAR T cells improves tumor control and survival in mouse models.
- Antigen density significantly influences the efficacy of CAR T-cell therapy against solid tumors.
- Concurrent treatment with MAPK inhibitors and CAR T cells is more effective than sequential treatment.
- TSHR expression declines rapidly after stopping MAPK inhibitor treatment.
Guideline-Based Recommendations
Diagnosis
Management
- Consider using MAPK inhibitors to enhance TSHR expression in thyroid cancer prior to CAR T-cell therapy.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with differentiated and anaplastic thyroid cancer.
Concurrent MAPK inhibitor treatment can improve CAR T-cell activity, but TSHR expression needs to be monitored post-treatment.
Clinical Best Practices
- Evaluate antigen expression levels in thyroid cancer before CAR T-cell therapy.
- Consider timing of MAPK inhibitor administration in relation to CAR T-cell therapy.
Related Resources & Content
